SnowBrand Treatment For Sjogren's Symptoms Evoxac Will Launch In Spring
SnowBrand Pharmaceuticals anticipates a spring launch for Evoxac (cevimeline), approved Jan. 11 for treatment of dry mouth symptoms in patients with Sjogren's syndrome.
You may also be interested in...
Daiichi Pharmaceuticals' 100-rep sales force will promote cevimeline for the treatment of dry mouth symptoms in patients with Sjogren's syndrome. Evoxac, expected to launch in early April, will be manufactured by Yamanouchi Pharma Technologies, Inc. (1"The Pink Sheet" Jan. 17, p. 25)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011